The disease-free survival of patients with myeloma and severe renal failure after high-dose melphalan and autologous stem cell rescue is similar to those with normal renal function at the time of the autograft. However, recovery of renal function after intensive treatment is uncommon and patients with end-stage renal failure continue to be dialysis-dependent. We report two patients with myeloma who required regular haemodialysis from diagnosis, but became dialysis-independent after a high-dose melphalan autograft. Thus, in some patients, renal function may be partially salvageable despite the requirement for dialysis at the time of autografting. Bone Marrow Transplantation (2002) 30, 471-473. doi:10.1038/sj.bmt.1703713 Keywords: myeloma; end-stage renal failure; stem cell transplantation There is emerging evidence that patients with myeloma and impaired renal function including those on haemodialysis should be offered treatment with high-dose melphalan (HDMel) and autologous stem cell rescue.
There is emerging evidence that patients with myeloma and impaired renal function including those on haemodialysis should be offered treatment with high-dose melphalan (HDMel) and autologous stem cell rescue. 1, 2 While renal function can improve after conventional chemotherapy in some patients with renal failure at diagnosis, 3 no significant improvement in renal function has been observed after HDMel. It has been suggested that the renal outcome after HDMel may be related to the type of paraprotein, as well as duration of myeloma. 1 We report two patients with endstage renal failure who became dialysis-independent after treatment with HDMel. Our experience indicates the potential for recovery of renal function after autografting even in patients requiring dialysis. Further studies on mechanisms that cause progressive and irreversible renal damage in myeloma may help identify patients in whom HDMel can potentially restore renal function. 
Patients

Patient 1
A 52-year-old male was investigated for a 10-week history of left-sided chest pain. X-rays revealed lytic lesions in the ribs and biopsy was consistent with plasmacytoma. He was anaemic (Hb 7.6 g/l), hypercalcemic (Ͼ3 mmol/l) and in renal failure (creatinine 690 mol/l). There was no serum paraprotein, but light chains were detected in the urine (75.49 g/gCr). The serum ␤2-microglobulin (␤2-M) level was 15.3 and plasma cell infiltrate in the marrow was 25% (stage 3B myeloma). Ultrasound of the kidneys was normal and renal biopsy showed distortion of most renal tubules by casts, surrounded by giant cells. These tubular defects suggested myeloma kidney.
A thrice weekly schedule of haemodialysis was started to treat acidosis and volume overload, and the patient received his first cycle of VAD chemotherapy (repeated every 3 weeks) 6 days after the diagnosis. The urinary paraprotein declined to 20.29 g/gCr after two cycles of VAD and re-staging investigations after four cycles of VAD indicated a decrease in marrow plasma cell infiltrate (5%). At this stage his serum ␤2-M and creatinine were 38.7 and 525 mol/l, respectively, and he continued on haemodialysis three times a week. Following the fifth cycle of VAD, peripheral blood stem cells were mobilized with G-CSF (10 g/kg/day) for 4 days.
Six months after the initial diagnosis, the patient was treated with high-dose melphalan (200 mg/m 2 ). Prior to melphalan therapy, glomerular filtration rate (GFR) measured by 51 Cr ethylene diamino tetracetate (EDTA) clearance was 9.6 ml/min, and serum creatinine was stable (360 mol/l). The thrice weekly schedule of haemodialysis was continued during the autograft and the patient was dialysed 24 h after receiving melphalan. Forty-eight hours after treatment with melphalan, he was infused with 6.3 ϫ 10 6 autologous CD34
+ cells/kg. Prophylactic ciprofloxacin (500 mg twice daily) was used until neutrophil recovery, and fluconazole (100 mg/day) and aciclovir (200 mg thrice daily) were continued until day +35. He was reviewed on a daily basis by the renal physicians.
The post-autograft period was relatively uncomplicated. Signs of platelet engraftment were evident on day +9. Oral mucositis (grade 2) and fever resolved with neutrophil engraftment (Ͼ0.5 on day +11) and he did not require G-CSF support. He was discharged from hospital on day +14. The creatinine remained stable and by day +19, the dialysis requirement had reduced to twice weekly. By day +43, haemodialysis was discontinued as he was euvolemic and normotensive with a stable creatinine (435 mol/l). At restaging investigations 3 and 6 months post-HDMel, no neoplastic plasma cells were detected in the marrow by immunophenotyping, and urinary paraprotein (0.12 g/gCr), serum ␤2-M (19) and creatinine (429 mol/l) were stable. Currently, 11 months after the autograft, he remains dialysisindependent and with stable disease.
Patient 2
A 57-year-old male presented with a 3-week history of loss of appetite. The serum creatinine was 1200 mol/l and haemoglobin 9.4 g/l. Serum calcium and skeletal survey were normal. IgG monoclonal band (71 g/l) was detected in serum along with urinary Bence-Jones protein (33.33 g/gCr). Serum ␤2-M levels were elevated (95.5). The plasma cell infiltrate in the marrow was Ͼ30% (stage 3B myeloma), with an abnormal hyperdiploid karyotype involving chromosomes 5, 10, 11, 15, 19, 21 and Y. Ultrasound of the kidneys was essentially unremarkable and renal biopsy revealed large numbers of intratubular hyaline casts and chronic parenchymal damage out of proportion to glomerular damage along with acute tubular damage. These features were consistent with a diagnosis of myeloma kidney.
A regular programme of alternate day dialysis was initiated, and the patient was commenced on VAD (repeated every 3 weeks) 12 days after the diagnosis. Restaging investigations after three courses of VAD indicated persistence of disease (marrow plasma cell infiltrate of 45% and IgG level of 60 g/l). He then received two cycles of salvage therapy with DT-ACE (dexamethasone 40 mg/day and thalidomide 400 mg/day orally and adriamycin 10 mg/m 2 , cyclophosphamide 400 mg/m 2 and etoposide 40 mg/m 2 as an intravenous infusion, for 4 days (platinum was omitted from the original schedule due to poor renal function) following which the IgG level declined to 43 g/l and plasma cell infiltrate to 8%. The serum ␤2-M level remained elevated (99.5) and creatinine was stable (787 mol/l) on thrice weekly haemodialysis. Peripheral blood stem cells were mobilised after the second cycle of DT-ACE using G-CSF (480 g/day for 5 days).
Five months after the initial diagnosis, the patient was treated with high-dose melphalan (200 mg/m 2 ). Prophylaxis against bacterial, fungal and viral prophylaxis was similar to that for patient 1. Serum creatinine prior to high-dose melphalan (809 mol/l) remained stable on haemodialysis three times a week and this schedule was continued during the autograft. The patient was reviewed on a daily basis by the renal physicians and dialysed 24 h after receiving melphalan. Forty-eight hours after melphalan therapy 14.32 ϫ 10 6 autologous CD34 + cells/kg were infused. He subsequently developed culture-negative neutropenic fever, severe oral mucositis (grade 4) and diarrhoea. Neutrophil engraftment was evident on day +10 after 4 days on G-CSF (300 g/day). Although the aetiology of the fever and diarrhoea was not conclusively identified, he became asymptomatic by day +28. Thereafter, he did not require platelet support (day +29). Two months postHDMel, the serum paraprotein had declined to 10.8 g/l. The frequency of haemodialysis was reduced to twice weekly at 5 months (creatinine 404 mol/l) and discontinued at 6 months after the autograft. Seven months postautograft, paraprotein was undetectable in serum and levels of ␤2-microglobulin (10) and creatinine (318 mol/l) were stable. Currently, 28 months after the autograft, he remains dialysis-independent and does not have detectable disease.
Discussion
In patients with myeloma on dialysis, despite differences in immediate post-transplant complications, the haematological outcome after HDMel is similar to those with normal renal function at the time of autografting.
1,2 However, renal function remains severely impaired and patients continue to be dialysis-dependent, thus compromising quality of life. In contrast, in patients who present with renal failure at diagnosis, serum biochemistry can normalise in a large proportion of cases with adequate hydration and chemotherapy. 4 It is thought that the severity and duration of renal failure may influence renal recovery after HDMel, and renal dysfunction may be irreversible in those who are dialysisdependent at the time of the autograft. The two patients we have described had haemodialysis-dependent renal failure at diagnosis, as well as at the time of HDMel. Despite this, both recovered renal function to the extent of becoming dialysis-independent after the autograft, suggesting that renal failure may be partially reversible following treatment with HDMel.
The partial recovery of renal function has been described in a subset of myeloma patients with severe renal failure receiving high-dose chemotherapy. Ballester et al 5 reported a decrease in dialysis requirements in 1/3 patients on haemodialysis at the time of the autograft. A decrease in the frequency of dialysis has also been reported in a minority of patients, 6 although there are few reports of patients becoming dialysis-independent post-autograft. Since both our patients were able to discontinue dialysis post-HDMel, renal function may be partly salvageable even in patients with histopathological features of 'myeloma kidney'. 7 The reasons for the significant improvement in renal function seen in the two patients are not clear: both achieved only partial remission with conventional infusional chemotherapy and levels of ␤2-microglobulin remained elevated at the time of treatment with HDMel, although the latter may have reflected poor renal function. Nevertheless, after the autograft (performed within 6 months of the original diagnosis), there was an appreciable decrease in tumour load in both patients along with an apparent improvement in renal function. It is possible that the use of HDMel at 200 mg/m 2 may have reduced the myeloma cell burden sufficiently rapidly to salvage renal function. Recent reports have suggested that this dose of melphalan may cause increased transplant-related morbidity in patients with renal failure;
1 previous studies have, however, indicated better progression-free and overall survival for patients treated with HDMel 200 mg/m 2 rather than a dose of 140 mg/m 2 . 8 Both our patients were therefore treated with the higher dose of HDMel. Although the tumour load appears to have satisfactorily been reduced using this regime, one patient (No. 2) had severe mucositis and prolonged fever after the autograft. In keeping with our experience, Sirohi et al 6 have reported increased toxicity, but better disease response, as well as partial recovery of renal function in patients on dialysis treated with HDMel200 rather than HDMel140. It has been suggested that low serum albumin may predict transplant-related complications in patients with renal failure treated with HDMel. 1 This may be reflected in the differences between the post-transplant period of the two patients we have reported: patient 1, with a serum albumin Ͼ35 g/dl had less mucositis and infectious complications than the second patient (albumin Ͻ35 g/dl).
Prospective randomised studies in eligible patients with severe renal failure or on dialysis may help to optimise the timing and dosage of HDMel, with a view to potentially improving renal function and minimising treatmentrelated toxicity. Identifying markers and mechanisms of irreversible renal damage in myeloma may also help select patients in whom renal function could benefit from treatment with HDMel, with a substantial improvement in quality of life.
